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Abstract 
While bisphosphonates reduce fracture risk over 3 to 5 years, the optimal duration of treatment is 
uncertain. In a randomized extension study (E1) of the Health Outcomes and Reduced Incidence 
with Zoledronic Acid Once Yearly  Pivotal Fracture Trial (HORIZONPFT), zoledronic acid 
(ZOL) 5 mg annually for 6 years showed maintenance of bone mineral density (BMD), decrease 
in morphometric vertebral fractures, and a modest reduction in bone turnover markers (BTMs) 
compared with discontinuation after 3 years. To investigate the longer-term efficacy and safety 
of ZOL, a second extension (E2) was conducted to 9 years in which women on ZOL for 6 years 
in E1 were randomized to either ZOL (Z9) or placebo (Z6P3) for 3 additional years. In this 
multicenter, randomized, double-blind study, 190 women were randomized to Z9 (n=95) and 
Z6P3 (n=95). The primary endpoint was change in total hip BMD at year 9 vs. year 6 in Z9 
compared with Z6P3. Other secondary endpoints included fractures, BTMs, and safety. From 
year 6 to 9, the mean change in total hip BMD was −0.54% in Z9 vs. −1.31% in Z6P3 
(difference 0.78%; 95% confidence interval [CI]: 0.37%, 1.93%; p=0.183). BTMs showed 
small, non-significant increases in those who discontinued after 6 years compared with those 
who continued for 9 years. The number of fractures was low and did not significantly differ by 
treatment. While generally safe, there was a small increase in cardiac arrhythmias (combined 
serious and non-serious) in the Z9 group but no significant imbalance in other safety parameters. 
The results suggest almost all patients who have received six annual ZOL infusions can stop 
medication for up to 3 years with apparent maintenance of benefits. This article is protected by 
copyright. All rights reserved 
Key words: Antiresorptives, Biochemical markers for bone turnover, Clinical trials, Fracture 
prevention, Osteoporosis 
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Introduction 
Bisphosphonates, the most commonly used treatment for osteoporosis, inhibit osteoclast-
mediated bone resorption and increase bone mineral density (BMD). Trials of 3–4 years duration 
have shown that these reduce the risk of vertebral, hip, and other non-vertebral fractures, 
particularly in women with established osteoporosis.
(1-6)
 Studies of longer term use of zoledronic 
acid (ZOL, up to 6 years) and alendronate (up to 10 years) have shown that in women who 
discontinue after 3–5 years of use, some benefits, including reduced bone loss and reduction in 
vertebral fractures, are retained.
(7)
 Retention of benefits after the use of risedronate is less 
apparent compared with alendronate 
(8)
 and there are no data available for ibandronate. Recent 
concerns about a possible association of bisphosphonates with osteonecrosis of the jaw (ONJ) 
and atypical femur fractures (AFF), particularly with long-term use, have led patients and 
clinicians to try to limit the duration of use.
(9)
 Therefore, it is important to provide long-term data 
about benefits vs. risks which can guide clinical decision-making regarding optimal duration of 
long-term bisphosphonate use. 
In the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly – Pivotal 
Fracture Trial (HORIZON–PFT), a single annual intravenous (IV) infusion of the ZOL 5 mg for 
3 years decreased the risk of spine, hip, and other non-vertebral fractures; increased BMD; and 
decreased the levels of bone re-modeling in women with postmenopausal osteoporosis.
(3)
 The 
first 3-year extension of HORIZON-PFT (E1) showed that the continuation of ZOL treatment 
from 3-6 years resulted in maintenance of BMD, a decrease in morphometric vertebral fractures, 
and a modest reduction in bone turnover markers (BTMs) vs. discontinuation with no evidence 
of difference in the incidence of non-vertebral fracture.
(10)
 In order to assess the long-term 
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efficacy and safety, and need for continued treatment with ZOL, we conducted a second 
extension of the HORIZON-PFT (E2), in which women on ZOL for 6 years in the first extension 
were randomized to either ZOL or placebo for 3 additional years, that is, for a total of up to 9 
years of treatment.  
Materials and Methods 
Study design and participants 
This was a 3-year, multicenter, randomized, double-blind, second extension (E2) study of the 
HORIZON-PFT. In the core study, 3889 women with postmenopausal osteoporosis were 
randomized to receive annual IV ZOL 5 mg and 3876 to receive placebo for 3 years.
(3)
 
Randomization was stratified by center. This was followed by the E1 study, in which 1233 
women who had originally received three ZOL infusions were randomized to receive three 
additional annual infusions of ZOL or placebo.
(10)
 The results from the core and E1 studies have 
previously been reported.
(3, 10)
 In this E2 study, women who had received at least the first and 
third doses of ZOL in E1 and completed the E1 study (n=451) were eligible. Patients with major 
protocol violations during the E1 study, specific bone-active medication use (e.g., use of oral 
bisphosphonates, strontium, and parathyroid hormone), and those with some other specific 
conditions were excluded (see online appendix, study protocol). All patients signed the written 
informed consent. The study was conducted according to the ethical principles of the Declaration 
of Helsinki (2008) and local applicable laws and regulations. The study is registered with 
ClinicalTrials.gov with the identifier NCT00718861. 
The study was jointly designed by the HORIZON-PFT Steering Committee and sponsor. The 
sponsor was responsible for data collection and quality control. Analyses for publication were 
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performed by the sponsor according to a pre-specified analysis plan developed by the first author 
and approved by the HORIZON-PFT Steering Committee. 
Randomization and treatment 
Eligible women were randomized (1:1) to receive either a 15-minute once-yearly IV infusion of 
ZOL (Z9 group) or placebo (Z6P3 group) for 3 additional years. The final visit of the patient in 
the E1 study (at year 6) served as the baseline and screening visit for this E2 study. In addition, 
all patients received daily oral calcium (1000 to 1500 mg) and vitamin D (400 to 1200 IU) as 
dietary supplements. All personnel involved in conduct of the study were blinded to treatment 
assignments including the study investigators, site personnel, the Novartis clinical team, as well 
as the clinical research organization and the University of California, San Francisco 
Coordinating Center personnel. To ensure blinding, patients were randomized centrally by an 
interactive voice response system. 
Endpoints 
The primary endpoint was percentage change in total hip BMD at year 9 relative to year 6 in Z9 
compared with Z6P3. The secondary endpoints included change in hip BMD (total and femoral 
neck) at years 7 and 8 vs. year 6 and at years 7, 8, and 9 vs. year 0. Other secondary endpoints 
included the incidence of fractures (morphometric vertebral and clinical fractures) at year 9 
relative to year 6 and change in BTMs at years 7, 8, and 9 relative to year 6. 
Efficacy measurements 
Total hip and femoral neck BMD were measured using dual x-ray absorptiometry (DXA). 
Quality control and BMD scan analyses were performed centrally (Synarc, Portland, OR, USA).  
Serum levels of procollagen type I N-terminal propeptide (PINP) were batch-assayed using 
archived serum collected at years 7, 8, and 9 in all participants. The numbers of PINP assay 
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results from years 0-6 are limited, reducing the numbers for longer-term comparisons. Other 
biochemical markers, C-terminal type 1 collagen telopeptide (β-CTx) and bone-specific alkaline 
phosphatase (BSAP), were measured in a small subset and compared with the E2 baseline 
(primary analysis) and also to the core study baseline. All assays were performed on the Roche 
Elecsys ElectroChemiLuminescence (Synarc, Lyon, France) platform. 
Fractures were assessed using methods identical to those in the core and E1 studies.
(3, 10)
 At each 
visit and at each quarterly telephone contact, patients were asked whether they had a fracture 
since the last visit. Clinical fractures were initially identified by self-report and a copy of the 
radiographic or surgical reports was sent for adjudication to the University of California, San 
Francisco Coordinating Center. The incidence of morphometric vertebral fractures was assessed 
by comparison of E2 baseline to the final study radiographs using the standard criteria that 
required both a quantitative morphometric change (20% or ≥4 mm) and a semiquantitative grade 
change ≥1. 
Safety assessment 
Safety was assessed by recording all self-reported adverse events (AEs) and serious AEs (SAEs); 
regular monitoring of hematology, blood chemistry, and urinary values; assessment of vital 
signs; and physical examinations. Renal safety was assessed by measuring serum creatinine and 
creatinine clearance (CrCl) on days 9 to 11 after each infusion. Potential renal events were pre-
defined by any of the following: (1) serum creatinine increase from either pre-infusion or E2 
baseline >0.5 mg/dL, (2) CrCl<30 mL/min, (3) CrCl decrease from E2 baseline ≥30% when E2 
baseline was ≤60mL/min, (4) protein urinary dipstick >2+, (5) reported AEs associated with a 
change in renal function. All potential renal events were submitted for adjudication. 
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AEs were categorized using the Medical Dictionary for Regulatory Activities. An independent 
Data Safety Monitoring Board met annually. Blinded, independent expert review committees 
reviewed and adjudicated information related to several AEs of interest: ocular events, 
hypocalcemia, maxillofacial complications (i.e. ONJ), skeletal events (e.g. avascular necrosis 
and delayed/nonunion following fractures), renal and relevant renal laboratory abnormalities, 
arrhythmia SAEs, and underlying cause of death. ONJ events were adjudicated based on the 
predefined criteria of “exposed bone of the jaw for more than 6 weeks”.(3, 11) All fractures of the 
hip and any region of the femur, except femoral neck, were referred for adjudication as AFF 
based on the revised criteria from the American Society for Bone and Mineral Research 
(ASBMR) requiring radiographic confirmation.
(12)
 All other non-serious AEs were based on self-
report only. Twelve-lead electrocardiogram (ECG) tests were conducted to assess pro-arrhythmic 
events following ZOL infusion. A total of 10 ECG tests could have been performed for each 
participant. ECG tests were performed prior to annual ZOL/placebo infusion at years 6, 7 and 8, 
and on days 9−11 and 76−104 post-annual infusions (all contributing to a total of 9 ECG tests). 
A final ECG test was performed at year 9. 
Statistical analyses 
The primary efficacy analysis used the modified intent-to-treat population including all patients 
in the intent-to-treat population who had undergone hip DXA measurements at years 6 and 9. 
The percentage change in total hip BMD at year 9 relative to year 6 was analyzed using an 
analysis of variance with treatment and geographic region as covariates. All tests were performed 
at 5% significance levels without adjustments for multiple comparisons.  
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BTMs were analyzed using loge transformation. Differences between Z9 and Z6P3 were 
evaluated using analysis of covariance on loge (ratio of year 9 and year 6 measurements) with 
treatment, geographic region, and loge (year 6 measurement) as explanatory variables. 
Between-treatment comparison of clinical fractures used a Cox regression model, with clinical 
fracture during the core and E1 studies as explanatory variables. The incidence of clinical 
fracture was estimated using the Kaplan–Meier method. New morphometric vertebral fractures 
were compared between the treatments using logistic regression with year 6 vertebral fractures 
(0, 1, and ≥2) as explanatory variables. 
AEs that occurred after the first dose during the E2 study were reported. If a patient reported 
more than one AE with the same preferred term, the patient was counted only once. Safety 
events were compared using the Fisher’s exact test. The categories of safety events were 
generally chosen to be consistent with the categories used in the core and first extension 
reports.
(3, 10)
 The proportion of patients with AEs were compared using a chi-squared test. 
Results  
A total of 451 women completed the E1 study with at least two infusions and therefore, met the 
broad criteria for eligibility. However, many clinics chose not to participate in this second 
extension study and some women or their physicians did not want to continue in a second 
randomized study leaving 190 women who were randomized into E2: Z9 (n=95) and Z6P3 
(n=95; Figure 1). Reasons for non-participation of the other 266 women are summarized in 
Figure 1. The mean age was 78 years (Table 1). The baseline characteristics were comparable 
between the treatment groups including hip BMD and proportion with vertebral fractures [Z9 
(58%) vs Z6P3 (55%)]. The baseline data was also found to be similar between treatment groups 
in patients who completed BMD and BTM assessments. The serum 25-OH-D was not measured 
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at baseline in this study. Discontinuations were similar between the two groups (21 in Z9 vs. 18 
in Z6P3, not significant). The most common reason for discontinuation was withdrawal of 
consent (Figure 1).  
Bone mineral density 
The mean change from year 6 to 9 in total hip BMD was −0.54% in Z9 compared with 1.31% 
in Z6P3 producing a mean between-group difference of 0.78% (95% confidence interval [CI]: 
0.37%, 1.93%; p=0.183). Small differences from years 6 to 8 were significant (Z9: −0.14 vs. 
Z6P3: 1.06%; p=0.033, Table 2A) whereas differences from years 6 to 7 did not significantly 
differ by treatment. Compared to the core study baseline (year 0) to year 9, there was no 
significant difference between the treatments in total hip BMD changes (Z9: 4.6% vs. Z6P3: 
3.7%, Figure 2A) or to years 7 or 8. Femoral neck BMD changes from year 6 to 7-9 did not 
significantly differ by treatment. Over the 9 years, there was about a 4% increase in femoral neck 
BMD, which did not differ by E2 treatment at any time point (Figure 2B). 
Bone turnover markers 
The mean serum levels of PINP and the other BTMs remained within the premenopausal 
reference range in both the groups (Figure 3A). In Z9, the percentage of patients with serum 
PINP values within the pre-menopausal reference range was 87.9%, 85.2% and 86.5% at years 7, 
8 and 9, respectively. Small increases from year 6 in the mean serum levels of PINP and β-CTx 
w re observed in both the Z9 and Z6P3 groups at years 7, 8 and 9 compared with year 6 (Figures 
3A and 3B). However, the difference between the groups in PINP was only significant at year 7 
(Table2B). For β-CTX and BSAP, fewer patients had data to assess the change. For β-CTX, 
there was no evidence of a difference by treatment. The pattern of change was similar for BSAP 
in Z6P3 (gradual increase over time), whereas almost no change was observed in Z9 from year 6 
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to years 7, 8 and 9. However, for BSAP, a statistically significant difference was observed 
between groups at year 9 (p=0.010, Figure 3C). Within the Z9, the mean BTM values increased 
from those in the early years of treatment (e.g. year 1): the within-group increase from year 1 
was significant for both PINP (p=0.004) and β-CTX (p=0.002). 
Fractures 
Fractures were too few for meaningful comparison. There were three morphometric vertebral 
fractures in Z9 and five in Z6P3 (3.2% vs. 5.3%, odds ratio=0.58, 95% CI: 0.13, 2.55; p=0.461, 
Figure 4A). Similarly, no significant difference in the risk of all clinical fractures was observed 
between the treatment groups. A total of 19 women (Z9 group: 10 patients, Z6P3 group: 9 
patients) suffered with 26 clinical fractures during the study. The estimated event rate was 12.2% 
in Z9 group and 9.5% in Z6P3 groups (hazard ratio=1.11, 95% CI: 0.45, 2.73; p=0.821 Figure 
4B). The Kaplan-Meier curve on time to first clinical fracture is presented in the Supplementary 
Figure. 
Height  
There were no significant differences in change in height from baseline between Z9 and Z6P3 at 
years 7, 8, and 9 relative to year 6. Least square (LS) mean changes from baseline in height in 
the Z9 and Z6P3 treatment groups, respectively, were −13.31 mm and −11.65 mm at Year 9 
(p=0.428); −10.16 mm and −9.90 mm at Year 8 ( p=0.896); and −5.29 mm and −4.84 mm at 
Year 7 (p=0.724). 
Safety 
Overall incidences of AEs and SAEs were similar in the two treatment groups (Table 3). One 
(1.1%) patient died in Z9 and five (5.3%) patients died in Z6P3 (hazard ratio = 0.20, 95% CI: 
0.02, 1.74; p=0.107). Over the 3 year study, at least one protocol-defined renal laboratory 
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abnormality occurred in 11% of patients of Z9 vs. 6.4% of patients in the Z6P3 group (p=0.304). 
Only one of the changes was seen at the 9-11 day follow-up assessment; the remainder were 
observed at one of the later annual follow-up visits. All the changes occurred in participants 
above 82 years of age. Other than AEs associated with these laboratory abnormalities, a total of 
eight clinically significant renal AEs were reported which did not differ by treatment (Table 3). 
Renal events (either laboratory abnormalities or AEs) were sent for adjudication in 11 patients in 
Z9 vs. 9 in Z6P3 and the total adjudicated as clinically significant was two in Z9 vs. three in 
Z6P3. Mean increases in serum creatinine from year 6 were slightly higher in Z9 vs. Z6P3 but 
these differences were small and not statistically significant (e.g. mean increases from years 6 to 
9 were 6.1 µmol/L in Z9 vs. 3.3 µmol/L in Z6P3, p=0.061). Similarly, the mean decreases in 
CrCl did not differ by treatment (years 6 to 9, −6.8 mL/min in Z9 vs. −5.6 mL/min in Z6P3, 
p=0.257). Cardiac arrhythmia AEs were reported in 14.1% of patients in Z9 vs. 4.2% of patients 
in the Z6P3 group (p=0.022). Atrial fibrillation was the most common arrhythmia observed in 
five patients in Z9 vs. one patient in Z6P3 (p=0.114). There was one SAE arrhythmia in Z9 
(atrial fibrillation) vs. three in Z6P3 (atrial fibrillation, arrhythmia and palpitations). Ischemic 
stroke was reported in one participant in Z9. None of the patients with atrial fibrillation reported 
a stroke. The electrocardiography (ECG) results showed no clinically important difference 
between the treatment groups. Although there were numerically more atrial fibrillation instances 
defined from ECG in Z9 (four patients) than Z6P3 (one patient), the difference was not 
significant. 
Six maxillofacial events were sent for adjudication (Z9=4, Z6P3=2) but no adjudicated 
confirmed ONJ cases were found. Four non-femoral neck femur fracture cases (one with 
radiograph and three with radiographic reports only) of potential AFF were sent for adjudication 
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but none were found after adjudication. Post-dose symptoms (<3 days after infusion) were rare 
and did not differ by treatment (Table 3). 
Death was reported (~8.5 months after the first infusion) in one patient due to malignancy (brain 
neoplasm), in the Z9 group. Five deaths were reported in the Z6P3 group; based on adjudication 
two deaths were ascribed to cardiac causes (sudden death for both), and for the other three, the 
underlying disease was unknown, although one of these patients was reported by the investigator 
to have died as a result of myocardial ischemia. On the basis of investigator assessment, the 
primary cause of death was not suspected to be related to the study medication in any of the 
cases. 
Discussion 
This second extension of the HORIZON-PFT allowed us to examine in a randomized, placebo-
controlled trial, the effect of 9 years of annual infusions of ZOL vs. 6 years followed by 3 years 
of placebo. A trend toward better maintenance of BMD in Z9 versus Z6P3 was observed, but the 
difference was small and there were minimal, if any, changes in bone turnover markers in those 
who continued vs. discontinued. The study did not have sufficient power to compare fracture 
rates. Taken together, the results show continued efficacy in both the groups and do not provide 
convincing evidence of a benefit from continuing annual ZOL infusions for more than 6 years. 
The BTM results are particularly interesting in reinforcing the bone safety of long-term use of 
ZOL as well as bisphosphonates in general. Prior to long-term studies of bisphosphonates, there 
were concerns that with continued use, bone turnover would progressively decrease leading to 
levels which might increase bone fragility. This study did not show a progressive decrease in the 
average bone turnover as assessed by PINP over 9 years of ZOL administration. In fact, the 
opposite was observed with a small, but steady, increase in the mean PINP after about 4 years of 
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continued treatment. While the patient numbers with other BTMs were quite small, the data were 
consistent with this trend in PINP. The fact that the incidence of vertebral fracture remained 
similar after 6 years to the rate observed in ZOL patients in the core phase of the trial, despite the 
patients’ older age, suggests that long-term continuation of ZOL is associated with maintenance 
of bone strength similar to that observed with shorter-term therapy. The randomized data from 
10 years of alendronate 
(7, 13)
 and more limited data for risedronate have been similarly reassuring 
in suggesting that long-term use will continue to maintain bone strength and sustained decreases 
in bone remodeling are not associated with any increase in overall fracture risk.  
It is of interest to compare the results from this second randomized extension from 6 to 9 years 
with the results seen during the E1 study from 3 to 6 years. In that study, we saw a trend toward 
a larger decrease in BMD from discontinuing ZOL vs. continuing (about 1.5% for hip BMD), 
after 6 years (about 0.8% for total hip) although a formal statistical comparison was not 
performed. While the confidence intervals in second extension study are wide, the results suggest 
the residual effect of ZOL after discontinuing may be more pronounced after 6 than after 3 years 
of use. Similarly, a larger difference in BTMs with stopping after 3 years compared to after 6 
years supports the view that continued use of ZOL for up to 6 years results in a larger residual 
effect after it is stopped. In the E1 study, those who continued ZOL experienced a significantly 
lower risk of morphometric vertebral fracture but similar risk of non-vertebral fracture leading us 
to recommend that women at high risk of vertebral fracture should be continued beyond 3 years. 
From this second extension to 9 years, there was a numerical reduction in vertebral fracture in 
those who continued, but numbers were much too small to draw a meaningful conclusion. As in 
the E1 study, we did not see evidence of reduction in clinical fractures but very small numbers 
preclude a definitive conclusion. 
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The only other comparable data for other bisphosphonates are for alendronate where the FLEX 
study had a similar design to our extensions but the initial period was longer (5 years) as was the 
first randomized extension (for another 5 years to a total of 10 years).The results of FLEX BMD 
were consistent with E1 as were the fracture results (a reduction in vertebral but not non-
vertebral fractures). However, the resolution of effect for BTMs stopping after 5 years of 
alendronate was more pronounced, suggesting that the residual effect of alendronate after 5 years 
is less than ZOL for 3 years and certainly less than ZOL after 6 years. Limited data for 
risedronate suggest a much faster resolution of effect than for alendronate, and there are no data 
available for ibandronate.  
The data from our long-term extension are consistent with the established safety profile of ZOL. 
For renal safety, we included a number of assessments. The overall number of participants 
meeting the pre-specified criteria for serum creatinine or CrCl changes was small and did not 
differ by treatment. Changes in CrCl did not differ by treatment and increases in serum creatinine 
were only slightly, but not significantly, larger in Z9 vs Z6P3. Taken together, the renal results 
did not suggest that concern regarding renal safety should play a role in the clinical decision 
about the length of ZOL use beyond 6 years. 
Increases in arrhythmias in general and atrial fibrillation in particular have been noted in some 
but not all studies of bisphosphonates. In the core ZOL study, there was a significant increase in 
serious AE atrial fibrillations but not in non-serious atrial fibrillation events among those on 
ZOL compared with placebo. In the E1, no significant difference for arrhythmias or either 
category of atrial fibrillation was observed in those who continued vs. those who stopped 
although atrial fibrillations were numerically more frequent in those who continued ZOL. In this 
study, we observed more arrhythmias (combined serious and non-serious) in the group on 
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continued ZOL treatment (13 vs. 4, p=0.022) but arrhythmias classified as serious did not differ 
in Z9 vs. Z6P3 (one vs. three, p=0.621) and arrhythmia assessed from ECG did not significantly 
differ by the treatment group. Another large randomized trial of ZOL in post-hip fracture patients 
with a mean age of 74.5 years did not show a difference in arrhythmias or atrial fibrillation 
between ZOL vs. placebo.
(14)
 For alendronate, a small but non-significant increase was also 
observed in arrhythmias in the FIT trial among those on alendronate.
 (15)
 However, other studies 
of alendronate and other oral bisphosphonates have not reported any increase. Possible effects of 
ZOL and other bisphosphonates on atrial fibrillation were added to the prescribing information 
for ZOL in 2008 as required by both the FDA and other regulatory agencies (MHRA and CHM). 
(http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085167) (Drug safety 
update from MHRA and CHM. 2008;1(12):4)  
Using the recent ASBMR criteria, we also observed no confirmed cases of AFF, although we did 
not have the radiographs to review in most cases. However, it should be noted that the incidence 
of AFF is much too low to be assessed in this study of 190 participants and we only had x-rays 
(required for recent ASBMR criteria) in one participant of the four that were sent for AFF 
adjudication. The recent ASBMR review suggests that the risk of AFF may be increased by 
longer duration of use but also notes the inconsistency in the evidence base with respect to 
duration of use.
(9)
  
Although this randomized trial is informative about the long-term use of ZOL, it also has some 
important limitations. As mentioned in statistical analyses, with only 190 patients, the study is 
underpowered to detect a difference in fracture rates, as well as the difference in some adverse 
events. Only about 451 patients had completed E1 on study medications in Z6, therefore, a much 
larger study was not possible. Another limitation is the relatively high rate of discontinuation 
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(about 27%) from the protocol although given the age of the patients and the length of the trial, 
this is perhaps difficult to avoid. 
In summary, in this extension of annual ZOL to 9 years, we showed little difference in efficacy 
between the patients who continued on active ZOL for 9 years compared with those who 
continued for 6 years and then discontinued for next 3 years. Overall, the 9-year study suggests 
sustained benefits on fracture and BMD from ZOL, but a diminishing return from its ongoing 
administration: a dramatic fracture benefit for 3 years of annual ZOL, more modest benefit for 6 
vs. 3 years and inconclusive benefits for 9 vs. 6 years of continued ZOL. Long-term treatment 
with ZOL for 9 years was found to well tolerated, as shown for other bisphosphonates, although 
there was a suggestion of a small increase in cardiac arrhythmias (combined serious and non-
serious)  between groups but no significant imbalance in other safety parameters. On balance, 
comparing the minimal additional benefit and the rare but possible safety issues, there is little 
compelling evidence for continuation of annual ZOL administration beyond 6 years. Therefore, 
almost all patients who receive ZOL for 6 years can probably stop the medication and expect 
continued benefit for up to 3 subsequent years. 
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Figure Legends 
Figure 1. Study flow chart. 
Figure 2. Mean changes in bone mineral density (BMD) over 9 years of treatment. 
(A) Total hip BMD from core study baseline to year 9 (ITT) and (B) femoral neck BMD from 
core study baseline to year 9 (ITT). Bracketed numbers are 95% confidence interval calculated 
based on a t-distribution. The numbers at the bottom of the figure panel show the number of 
available measurements at each time point. The LS mean difference is the percentage change in 
BMD from baseline. For the core and E1 study periods, only values for those continuing in the 
E2 study are shown. 
BMD, bone mineral density; ITT, intention-to-treat; LS, least square. 
Figure 3. Mean changes in bone turnover markers over 9 years of treatment.  
Serum PINP; (B) β-CTX, and (C) BSAP. Horizontal dashed lines represent premenopausal 
reference range.
9
 The numbers at the bottom of the figure panel show the number of available 
measurements at each time point and the mean is based on this total. For the core and E1 study 
periods, only values for those continuing in the E2 study are shown. The results represent 
geometric means. Statistical significance is based on comparison of values at year 9 (not 
change). 
β-CTX, beta C-terminal type 1 collagen telopeptide; BSAP, bone-specific alkaline phosphatase; 
PINP, procollagen type I N-terminal propeptide. 
Figure 4. The incidence of morphometric vertebral fractures and clinical fractures during 
the E2 study.  
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(A) Morphometric vertebral fractures and (B) all clinical fractures. For clinical fractures, the 
event rate is estimated from the Kaplan–Meier curve at month 36. The dashed lines indicate the 
incidence in the core trial by core treatment for the corresponding fracture types. 
CI, confidence interval; PBO, placebo; ZOL, zoledronic acid. 
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Table 1. Baseline characteristics of the study population of 190 subjects in the HORIZON-PFT 
E2 study 
Variables Z9  
(N=95) 
Z6P3  
(N=95) 
Age, years (mean ± SD) 
>70–75, n (%) 
>75–80, n (%) 
>80, n (%) 
78.0 ± 4.71 
32 (33.7) 
35 (36.8) 
28 (29.5) 
78.1 ± 4.85 
33 (34.7) 
37 (38.9) 
25 (26.3) 
Mean BMI (± SD), kg/m
2
 24.6 ± 4.13 25.0 ± 3.98 
Region, n (%) 
Western Europe 
Eastern Europe 
North America/Oceania 
Latin America/Asia 
 
39 (41.1) 
21 (22.1) 
19 (20.0) 
16 (16.8) 
 
37 (38.9) 
22 (23.2) 
19 (20.0) 
17 (17.9) 
Mean BMD (± SD), g/cm
2
 
Total hip
a
 
Femoral neck 
N=94 
0.69 ± 0.09 
0.58 ± 0.08 
N=95 
0.71 ± 0.09 
0.58 ± 0.07 
Mean femoral neck T-score, (± SD) −2.44 ± 0.72 −2.43 ± 0.6 
T-score at femoral neck, n (%) 
≤ −2.5 
>−2.5 to −1.5 
> −1.5 
N=94 
44 (46.3) 
43 (45.3) 
7 (7.4) 
N=95 
42 (44.2) 
47 (49.5) 
6 (6.3) 
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Bone turnover markers , (ng/mL) 
β-CTx, median (n) 
BSAP, median (n) 
PINP, median (n) 
 
0.19 (59) 
8.16 (59) 
     25.9 (88) 
 
0.18 (58) 
8.95 (62) 
  25.0 (86) 
Prevalent vertebral fracture,
a
 n (%) 
0 
1 
≥2 
 
40 (42.1) 
32 (33.7) 
23 (24.2) 
 
43 (45.3) 
22 (23.2) 
30 (31.6) 
Number of study drug infusions 
received during the core and first 
extension study  
5 infusions 
6 infusions 
 
 
 
3 (3.2) 
92 (96.8) 
 
 
 
2 (2.1) 
93 (97.9) 
± Values are means ± SD. 
a
None of the differences between treatment groups are statistically significant at p=0.05.  
BMD, bone mineral density; BMI, body mass index; BSAP, bone-specific alkaline phosphatase; 
β-CTx, beta C-terminal type 1 collagen telopeptide; HORIZON-PFT, Health Outcomes and 
Reduced Incidence with Zoledronic Acid Once Yearly - Pivotal Fracture Trial; PINP, Serum 
procollagen type I N-terminal propeptide; SD, standard deviation.  
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Table 2A. Between-treatment comparison in percentage change in bone mineral density at years 
7, 8, and 9 relative to year 6 (ITT) 
Location  Year of 
assessment 
from core 
study 
baseline 
(mean [SD] 
time to 
follow-up) 
Treatment n Mean change 
(%) 
Mean % difference 
(95% CI) 
p value 
Total hip  Year 7 
(7.3 [0.26]) 
Z9 
Z6P3 
83 
76 
−0.28 
−0.83 
0.55 (0.39, 1.49) 
 
0.248 
 Year 8 
(8.3 [0.28]) 
Z9 
Z6P3 
73 
72 
−0.14 
−1.06 
0.92 (0.07, 1.76) 0.033 
 Year 9
a 
(9.3 [0.27]) 
Z9 
Z6P3 
67 
69 
−0.54 
−1.31 
0.78 (0.37, 1.93) 0.183 
Femoral 
neck 
Year 7 
(7.3 [0.26]) 
Z9 
Z6P3 
83 
76 
−0.78 
−1.24 
0.46 (0.75, 1.67) 0.454 
 Year 8 
(8.3 [0.28]) 
Z9 
Z6P3 
73 
72 
0.00 
−0.88 
0.88 (0.53, 2.30) 0.220 
 Year 9 
(9.3 [0.27]) 
Z9 
Z6P3 
67 
69 
−1.11 
−1.17 
0.06 (1.41, 1.53) 0.935 
n is the number of patients with values at year 6 and the follow-up visit. 95% CI is calculated 
based on a t-distribution for BMD. p value is obtained from ANOVA with treatment and region 
as explanatory variables. 
a
MITT population
 
. 
 
ANOVA, analysis of variance; CI, confidence interval; ITT, intent-to-treat; LS, least squares; 
MITT, modified-intent-to-treat population.
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Table 2B Between-treatment comparison in percentage change in procollagen type I N-terminal 
propeptide (PINP) at years 7, 8, and 9 relative to year 6 (ITT) 
Parameter Visit Treatment n g-LSM (95% CI) 
of ratio
a
 
Relative 
treatment 
effect
b
 (95% CI)
c
 
p value 
PINP Year 7 Z9 
Z6P3 
56 
61 
0.97 
1.19 
0.82 (0.73, 0.92) 0.0007 
 Year 8 Z9 
Z6P3 
52 
53 
0.99 
1.09 
0.91 (0.81, 1.02) 0.094 
 Year 9 Z9 
Z6P3 
50 
52 
1.09 
1.23 
0.88 (0.76, 1.02) 0.100 
n is the number of patients with values at year 6 and the follow-up visit. 
p value is obtained from an analysis of covariance model on loge (visit/baseline measurement) 
with treatment, region, and loge (baseline measurement) as explanatory variables.  
 
a
Geometric LSM (g-LSM) of ratio is the exponential of LSM on the loge (visit/baseline 
measurement). 
b
Relative treatment effect is the exponential of LSM difference on loge 
(visit/baseline measurement). 
c
95% CI is calculated by anti-log inversing the 95% CI for loge 
(visit/baseline measurement). 
ANOVA, analysis of variance; CI, confidence interval; ITT, intent-to-treat; LSM, least square 
mean; PINP, procollagen type I N-terminal propeptide.  
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Table 3. Number of participants with adverse events 
Adverse events Z9 
(N=92) 
n (%) 
Z6P3 
(N=95) 
n (%) 
p value 
General 
Total subjects with any AE 
Total subjects with any SAE 
Total deathsa 
Total discontinuations due to AE 
 
80 (87.0) 
24 (26.1) 
1 (1.1) 
5 (5.4) 
 
80 (84.2) 
28 (29.5) 
5 (5.3) 
8 (8.4) 
 
0.679 
0.628 
0.212 
0.568 
Renal abnormalities based on laboratory 
measurements 
Increase in serum creatinine >0.5 mg/dLb 
Urinary protein dipstick > 2+c 
Calculated CrCl < 30 mL/mind 
CrCl decrease from baseline ≥ 30 % with 
               E2 baseline value ≤ 60 mL/mine 
Any of the above in years 7–9 
 
Clinically significant renal AEsf 
Renal failure  
Renal impairment      
Acute prerenal failure       
Renal failure acute 
 
 
 
1 (1.1) 
1 (1.3)  
7 (8.2) 
 
5 (7.9)  
10 (11.0) 
 
 
2 (2.2) 
2 (2.2) 
0 (0.0) 
0 (0.0) 
 
 
 
1 (1.1) 
0 (0.0) 
3 (3.5) 
 
3 (5.3)  
6 (6.4) 
 
 
1 (1.1) 
1 (1.1) 
1 (1.1) 
1 (1.1) 
 
 
 
1.000 
1.000 
0.211 
 
0.493 
0.304 
 
 
0.617 
0.617 
1.000 
1.000 
 
Most commonly occurring post-dose 
symptoms (<3 days)g 
Pyrexia 
 
 
2 (2.2) 
 
 
0 (0.0) 
 
 
0.241 
Myalgia 1 (1.1) 2 (2.1) 1.000 
Influenza-like illness 1 (1.1) 0 (0.0) 0.492 
Headache  
Any of the above in years 7-9 
1 (1.1) 
5 (5.4) 
0 (0.0) 
2 (2.1) 
0.492 
0.273 
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Cardiovascular AEs 
Arrhythmia 
Any AEh 
SAEi 
Atrial fibrillation  
Any AE  
SAE 
Myocardial infarction  
Any AE  
SAE 
Ischemic stroke  
Any AE  
SAE 
 
Hypertension Any AE 
 
 
13 (14.1) 
1 (1.1) 
 
5 (5.4) 
1 (1.1) 
 
0 (0.0) 
0 (0.0) 
 
1 (1.1) 
1 (1.1) 
 
10 (10.9) 
 
 
 
4 (4.2) 
3 (3.2) 
 
1 (1.1) 
1 (1.1) 
 
1 (1.1) 
1 (1.1) 
 
0 (0.0) 
0 (0.0) 
 
8 (8.4) 
 
 
0.022 
0.621 
 
0.114 
1.000 
 
1.000 
1.000 
 
0.492 
0.492 
 
0.626 
AE, adverse event; SAE, serious adverse event; CrCl, creatinine clearance; E2, extension 2 
a
On the basis of investigator assessment, the primary cause of death was not suspected to be 
related to the study medication in any of the cases. 
b
Increase in serum creatinine >0.5 mg/dL (Z9: N=91, Z6P3: N=94), one patient in the Z6P3 
group reported an increase in serum creatinine at the 9-11 day measurement following the Year 8 
zoledronic acid infusion. 
c
Urinary protein dipstick >2+ (Z9: N=80, Z6P3: N=80), an extension criterion of baseline 
urinary protein dipstick ≤2+ is required.  
d
CrCl <30 mL/min (Z9: N=85, Z6P3: N=86), an extension criterion of baseline creatinine 
clearance ≥30 mL/min is required. 
e
CrCl decrease from baseline ≥30% with baseline value ≤60 mL/min (Z9: N=63, Z6P3: N=57), 
E2 baseline CrCl ≤60 mL/min is required. 
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f
Of the significant renal AEs, two were reported as serious in one patient in the Z6P3 group: 
acute prerenal failure and renal failure acute. These events were sent for adjudication and the 
outcome was indeterminate. 
g
The four most common AEs reported within 3 days of infusion in the ZOL group in the core and 
E1 studies. There were no reported arthralgias during the days following infusions. 
h
Arrhythmia AEs include atrial fibrillation (total=6; Z9=5, Z6P3=1), atrioventricular block first 
degree (total=2; Z9=2, Z6P3=0), bundle branch block left (total=2; Z9=2, Z6P3=0), bundle 
branch block right (total=2; Z9=2, Z6P3=0), arrhythmia (total=2; Z9=1, Z6P3=1), sinus 
bradycardia (total=1; Z9=1, Z6P3=0), supraventricular extrasystoles (total=1; Z9=0, Z6P3=1), 
tachycardia (total=1; Z9=0, Z6P3=1), and ventricular extrasystoles (total=1; Z9=0, Z6P3=1). 
i
Arrhythmia SAEs include atrial fibrillation (total=2; Z9=1, Z6P3=1), arrhythmia (total=1; Z9=0, 
Z6P3=1), and palpitations (total=1; Z9=0, Z6P3=1). 
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